11 research outputs found
7. Tropendermatologischer Kurs der Deutschen Dermatologischen Gesellschaft (DDG) und der Internationalen Gesellschaft fĂŒr Dermatologie in den Tropen (ISDT) in Manaus/Brasilien im Oktober 2019
Vanegas A, Effendy I, Schöfer H. 7. Tropendermatologischer Kurs der Deutschen Dermatologischen Gesellschaft (DDG) und der Internationalen Gesellschaft fĂŒr Dermatologie in den Tropen (ISDT) in Manaus/Brasilien im Oktober 2019. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2020;18(5):529-530.Tagungsberich
Erythema of Rosacea Impairs Health-Related Quality of Life: Results of a Meta-analysis
<p><b>Article full text</b></p>
<p><br></p>
<p>The full text of this article can
be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s13555-016-0106-9">https://link.springer.com/article/10.1007/s13555-016-0106-9</a></p>
<p><br></p>
<p><b>Provide enhanced content for this
article</b></p>
<p><br></p>
<p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/ĂąÂÂmailto:[email protected]ĂąÂÂ"><b>[email protected]</b></a>.</p>
<p><br></p>
<p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p>
<p><br></p>
<p>Other enhanced features include,
but are not limited to:</p>
<p><br></p>
<p>âą Slide decks</p>
<p>âą Videos and animations</p>
<p>âą Audio abstracts</p>
<p>âą Audio slides</p
Sinecatechins and imiquimod as proactive sequential therapy of external genital and perianal warts in adults
This review about the proactive sequential therapy (PST) of external genital and perianal warts (EGW) is based on the most current available clinical literature and on the broad clinical experience of a group of international experts, physicians who are well versed in the treatment of human papillomavirus-associated diseases. It provides a practical guide for the treatment of EGW, including epidemiology, etiology, clinical appearance, and diagnostic procedures for these viral infections. Furthermore, the treatment goals and current treatment options, elucidating provider- and patient-applied therapies, and the parameters driving treatment decisions are summarized. Specifically, the mode of action of the topical treatments sinecatechins and imiquimod, as well as the PST for EGW to achieve rapid and sustained clearance is discussed. The group of experts has developed a treatment algorithm giving healthcare providers a practical tool for the treatment of EGW which is very valuable in the presence of many different treatment options
Diagnosis and treatment of Staphylococcus aureus-induced infections of the skin and mucous membranes: S2k and IDA guidelines
Schöfer H, Bruns R, Effendy I, et al. Diagnosis and treatment of Staphylococcus aureus-induced infections of the skin and mucous membranes: S2k and IDA guidelines. Chemotherapie-Journal (CTJ). 2011;20(5):141-156
Diagnosis and treatment of Staphylococcus aureus infections of the skin and mucous membranes
Schöfer H, Bruns R, Effendy I, et al. Diagnosis and treatment of Staphylococcus aureus infections of the skin and mucous membranes. Journal der Deutschen Dermatologischen Gesellschaft. 2011;9(11):953-967
Sinecatechins and imiquimod as proactive sequential therapy of external genital and perianal warts in adults
S2k guideline: Rosacea
This updated and upgraded S2k guideline deals with the diagnosis and treatment of rosacea, which is a common, chronic inflammatory skin disease mostly affecting the face. Initially, rosacea is characterized by recurrent erythema, telangiectasia and flushing. Later, the inflammatory component predominates, with persistent erythema with follicular papules, papulopustules and pustules. The development of phyma, which usually occurs on the acral localizations, is the most severe manifestation. For the treatment of rosacea, the interdisciplinary guideline committee, with representatives of the German Dermatological Society (DDG), the Professional Association of German Dermatologists (BVDD), the German Opthalmological Society (DOG), the Society for Dermopharmacy (GD), the Swiss Society for Dermatology and Venereology (SGDV) and the German Rosacea Aid e. V., recommends the avoidance of trigger factors and topical applications of metronidazole, azelaic acid or ivermectin. For symptomatic treatment of persistent centrofacial erythema, the topical vasoconstrictors brimonidine or oxymetazoline can also be used. Systemic therapy is recommended for therapy-resistant and severe forms of rosacea papulopustulosa. The drug of choice is low-dose doxycycline. Alternatively, low-dose isotretinoin can be recommended. Ocular rosacea should be treated with lid margin hygiene. For topical treatment, ciclosporin eye drops, azithromycin, ivermectin or metronidazole are suggested